4-butyrolactone has been researched along with 5-(tetradecyloxy)-2-furancarboxylic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuhajda, FP; McFadden, JM; Medghalchi, SM; Pinn, ML; Ronnett, GV; Simpson, PJ; Townsend, CA; Vadlamudi, A; Zhou, W | 1 |
| Chen, Q; Li, LF; Liu, JY; Lu, YY; Xiong, W | 1 |
2 other study(ies) available for 4-butyrolactone and 5-(tetradecyloxy)-2-furancarboxylic acid
| Article | Year |
|---|---|
Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells.
Topics: 4-Butyrolactone; Apoptosis; Breast Neoplasms; Carnitine O-Palmitoyltransferase; Cell Division; Cell Line, Tumor; Drug Interactions; Epoxy Compounds; Fatty Acid Synthases; Furans; Humans; Membrane Lipids; Phospholipids; S Phase | 2003 |
Effect of centrally administered C75, a fatty acid synthase inhibitor, on gastric emptying and gastrointestinal transit in mice.
Topics: 4-Butyrolactone; Acetyl-CoA Carboxylase; Animals; Brain; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fasting; Fatty Acid Synthases; Furans; Gastric Emptying; Gastrointestinal Transit; Ghrelin; Injections, Intraventricular; Male; Mice | 2008 |